FINACEA GEL
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
18-09-2019
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
AZELAIC ACID
Tillgänglig från:
LEO PHARMA INC
ATC-kod:
D10AX03
INN (International namn):
AZELAIC ACID
Dos:
15%
Läkemedelsform:
GEL
Sammansättning:
AZELAIC ACID 15%
Administreringssätt:
TOPICAL
Enheter i paketet:
15G/50G
Receptbelagda typ:
Prescription
Terapiområde:
MISC. SKIN AND MUCOUS MEMBRANE AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0126787002; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2005-09-02
Produktens egenskaper
_FINACEA Product Monograph, version 1.0_
_Page 1 of 20 _
PRODUCT MONOGRAPH
PR FINACEA
®
Azelaic Acid Gel
15% w/w
Topical
Antirosacea Agent
LEO Pharma Inc.
Thornhill, Ontario
L3T 7W8
www.leo-pharma.ca
Submission Control No.: 229634
Date of Revision:
September 18, 2019
®Registered trademark of LEO Pharma A/S used under license by LEO
Pharma Inc., Thornhill, ON
_FINACEA Product Monograph, version 1.0_
_Page 2 of 20 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................7
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
SPECIAL HANDLING INSTRUCTIONS
.........................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
PART II: SCIENTIFIC INFORMATION
...............................................................................10
PHARMACEUTICAL INFORMATION
................................................
Läs hela dokumentet
